# A Study for Tysabri Participant Preference

> **NCT05304520** · — · COMPLETED · sponsor: **Biogen** · enrollment: 318 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis (RRMS)

## Interventions

- **DRUG:** Natalizumab

## Key facts

- **NCT ID:** NCT05304520
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-12
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 318 (ACTUAL)
- **Last updated:** 2024-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05304520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05304520, "A Study for Tysabri Participant Preference". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05304520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*